GEN Exclusives

More »

GEN News Highlights

More »
Jun 16, 2014

Horizon, LGC Awarded Research Grant for Cancer Diagnostics

  • Horizon Discovery and LGC have been offered a research grant of £360,224 ($608,000) by the Technology Strategy Board, the U.K.’s innovation agency. The grant is awarded under the board’s collaborative research and development project "Improving Cell and Tissue Analysis for Stratified Medicine" and will fund a joint project run by the company’s Horizon Diagnostics division in partnership with LGC. Horizon will receive more than half of the funding.

    The program will establish methods and cross platform datasets to standardize existing liquid biopsy genetic diagnostic tests to determine test sensitivity and to help drive the development of more sensitive systems as well as training and proficiency testing schemes for pathology laboratories. 

    Horizon will use its gene editing expertise and GENESIS™ platform (comprising rAAV, CRISPR/Cas9, and ZFN technologies) to engineer cell lines carrying cancer genetic markers. These cell lines will be used to generate reference standard material including formalin-fixed paraffin embedded cell blocks and genomic DNA. LGC, which is the U.K.’s designated National Measurement Institute for chemical and bioanalytical measurement, is developing methods using digital PCR for accurate value assignment of reference materials and will test the reference standard material produced by Horizon. LGC is also developing these methods to detect tumor DNA in the bloodstream.

    “Horizon is committed to investing in new, innovative areas related to cancer and diagnostics, supporting the increased implementation of stratified and personalized intervention strategies,” said Paul Morrill, Ph.D., senior vice president of Reagent Products at Horizon.

    “The combination of Horizon’s reference materials and LGC’s assays—PCR primers and probes—gives the potential for development of kits that clinical laboratories can use with their existing platforms,” said Carole Foy, principal scientist from LGC’s molecular and cell biology department. “These standardization tools will be invaluable in ensuring the accuracy of the results when detecting tumor DNA in the bloodstream.”

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Patients Access to Experimental Medicines?

More »